Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Blackstone announced today that funds managed by Blackstone Life Sciences (“Blackstone”) will provide $750 million in development funding to Johnson & Johnson to support the Phase 3 clinical development of OLN324, an investigational therapy for serious retinal vascular diseases.Specifically, Blackstone will finance the Phase 3 clinical program of OLN324, including wet age-related macular degeneration and diabetic macular edema, following the expected closing of the acquisition of Ollin Biosciences, Inc. (“Ollin”).
“We are pleased to expand our relationship with Johnson & Johnson by supporting the Phase 3 development of OLN324,” said Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences. “Our financing demonstrates our ability to provide capital at scale to help leading pharmaceutical companies pursue strategic opportunities and advance innovative medicines that have the potential to improve patients’ lives.”
“OLN324 has demonstrated encouraging early clinical results and represents a differentiated approach to treating serious retinal vascular diseases that could deliver meaningful benefits for patients,” said Kiran Reddy, Senior Managing Director at Blackstone Life Sciences. “We are excited to work with Johnson & Johnson to help advance this promising new treatment option to patients.”
The agreement is subject to the acquisition of Ollin by Johnson & Johnson, which is subject to customary closing conditions including receipt of regulatory approvals.As part of its investment, Blackstone is entitled to certain regulatory and sales milestone payments as well as single digit royalties.
About Blackstone Life Sciences
Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has $18 billion in assets under management.
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
wet age-related macular degenerationmedical
A severe eye condition in which abnormal, fragile blood vessels grow beneath the macula — the small central part of the retina responsible for sharp, detailed vision — and leak fluid or blood, causing rapid loss of central sight. Investors care because the condition drives demand for high-cost therapies, medical devices and ongoing care; successful treatments can create sizable markets, affect healthcare spending and influence regulatory and reimbursement decisions, much like fixing a leaking camera lens restores image quality and value.
diabetic macular edemamedical
Diabetic macular edema is an eye condition in which fluid leaks into and swells the macula, the part of the retina used for sharp, central vision, often as a complication of diabetes. For investors it matters because it drives demand for medicines, medical devices and eye-care services, influences clinical trial and regulatory outcomes, and can affect healthcare costs and revenue forecasts—think of the macula as the camera’s central lens that becomes blurred when it soaks up excess fluid.